How do you choose between regorafenib or TAS-102 in patients with metastatic colorectal carcinoma that has progressed on all prior 5-FU based regimens and anti-EGFR therapy?  

Despite their FDA approval, both TAS-102 and regorafenib are equally marginal drugs in terms of their efficacy. In the world of GI Oncology, there are those of us who do and do not treat HCC; those who do have experience with sorafenib and regorafenib and find both drugs to be "tolerable". On the ot...

It is worth noting the Rego Nivo data presented at ASCO 2019 showed promising preliminary activity in MSS colorectal cancer in a Japanese population of patients. Patients in the dose-escalation cohort were given 80 mg, 120 mg, or 160 mg of regorafenib once per day for 21 days with 7-day gaps in the ...